Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2015, Article ID 796215, 11 pages
Research Article

Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches

1Human Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil
2Laboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil
3Stomatology Department, Faculty of Dentistry, University of São Paulo, 05508-000 São Paulo, SP, Brazil

Received 26 December 2014; Revised 9 March 2015; Accepted 10 March 2015

Academic Editor: Luca Magnani

Copyright © 2015 T. Jazedje et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The use of Mesenchymal Stromal Cells (MSCs) aiming to treat cancer has shown very contradictory results. In an attempt to clarify the contradictory results reported in the literature and the possible role of human fallopian tube Mesenchymal Stromal Cells (htMSCs) against breast cancer, the aim of this study was to evaluate the clinical effect of htMSCs in murine mammary adenocarcinoma using two different approaches: (1) coinjections of htMSCs and 4T1 murine tumor cell lineage and (2) injections of htMSCs in mice at the initial stage of mammary adenocarcinoma development. Coinjected animals had a more severe course of the disease and a reduced survival, while tumor-bearing animals treated with 2 intraperitoneal injections of 106 htMSCs showed significantly reduced tumor growth and increased lifespan as compared with control animals. Coculture of htMSCs and 4T1 tumor cells revealed an increase in IL-8 and MCP-1 and decreased VEGF production. For the first time, we show that MSCs isolated from a single source and donor when injected in the same animal model and tumor can lead to opposite results depending on the experimental protocol. Also, our results demonstrated that htMSCs can have an inhibitory effect on the development of murine mammary adenocarcinoma.